Travere Historical Balance Sheet
TVTX Stock | USD 21.10 0.13 0.61% |
Trend analysis of Travere Therapeutics balance sheet accounts such as Total Stockholder Equity of 56.1 M, Net Debt of 360.2 M, Accounts Payable of 13.9 M or Cash of 58.4 M provides information on Travere Therapeutics' total assets, liabilities, and equity, which is the actual value of Travere Therapeutics to its prevalent stockholders. By breaking down trends over time using Travere Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Travere Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Travere Therapeutics is a good buy for the upcoming year.
Travere Therapeutics Inventory |
|
Travere |
About Travere Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Travere Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Travere Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Travere Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Travere currently owns. An asset can also be divided into two categories, current and non-current.
Travere Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Travere Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Travere Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Travere Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Travere Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Travere Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Travere Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.At this time, Travere Therapeutics' Net Working Capital is fairly stable compared to the past year. Property Plant Equipment is likely to rise to about 11.8 M in 2025, whereas Total Assets are likely to drop slightly above 474.5 M in 2025.
2022 | 2023 | 2024 | 2025 (projected) | |
Short and Long Term Debt Total | 407.5M | 404.8M | 401.6M | 421.7M |
Total Assets | 672.6M | 788.9M | 594.1M | 474.5M |
Travere Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Travere Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Travere Therapeutics balance sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 607.4M | 776.6M | 672.6M | 788.9M | 594.1M | 474.5M | |
Short Long Term Debt Total | 215.7M | 262.0M | 407.5M | 404.8M | 401.6M | 421.7M | |
Other Current Liab | 80.5M | 84.9M | 104.0M | 124.2M | 100.3M | 64.0M | |
Total Current Liabilities | 92.7M | 124.1M | 142.2M | 177.9M | 200.8M | 210.8M | |
Total Stockholder Equity | 211.2M | 302.1M | 42.9M | 200.8M | 59.1M | 56.1M | |
Net Debt | 130.6M | 96.2M | 345.8M | 346.6M | 343.0M | 360.2M | |
Retained Earnings | (585.9M) | (766.0M) | (1.0B) | (1.1B) | (1.4B) | (1.4B) | |
Accounts Payable | 12.1M | 15.1M | 17.3M | 41.7M | 23.5M | 13.9M | |
Cash | 84.8M | 165.8M | 61.7M | 58.2M | 58.5M | 58.4M | |
Cash And Short Term Investments | 361.6M | 552.9M | 450.2M | 566.9M | 370.7M | 292.8M | |
Common Stock Shares Outstanding | 47.5M | 59.8M | 63.8M | 74.3M | 78.9M | 48.4M | |
Liabilities And Stockholders Equity | 607.4M | 776.6M | 672.6M | 788.9M | 594.1M | 474.5M | |
Non Current Liabilities Total | 303.6M | 350.4M | 487.6M | 410.2M | 334.3M | 215.1M | |
Other Stockholder Equity | 798.0M | 1.1B | 1.1B | 1.3B | 1.5B | 1.6B | |
Total Liab | 396.2M | 474.5M | 629.7M | 588.1M | 535.0M | 313.3M | |
Total Current Assets | 410.4M | 582.8M | 486.4M | 616.8M | 416.7M | 325.8M | |
Short Term Debt | 357K | 7.8M | 8.9M | 4.9M | 74.1M | 77.8M | |
Property Plant And Equipment Net | 9.4M | 34.3M | 30.0M | 25.5M | 19.6M | 11.2M | |
Current Deferred Revenue | (357K) | 16.3M | 12.0M | 7.1M | 2.8M | 2.7M | |
Non Current Assets Total | 197.0M | 193.8M | 186.1M | 172.1M | 177.4M | 171.5M | |
Non Currrent Assets Other | 33.5M | 11.1M | 11.1M | 42.2M | 53.8M | 56.5M | |
Other Current Assets | 8.1M | 6.7M | 15.0M | 19.3M | 12.7M | 8.4M | |
Intangible Assets | 153.2M | 148.4M | 145.0M | 103.7M | 104.0M | 138.4M | |
Short Term Investments | 276.8M | 387.1M | 388.6M | 508.7M | 312.2M | 292.9M | |
Property Plant And Equipment Gross | 9.4M | 34.3M | 30.0M | 33.0M | 28.4M | 29.8M | |
Accumulated Other Comprehensive Income | (902K) | (562K) | (2.9M) | (1.5M) | (80K) | (84K) | |
Net Receivables | 33.1M | 15.9M | 16.6M | 21.2M | 27.1M | 21.3M | |
Inventory | 7.6M | 7.3M | 6.9M | 9.4M | 6.2M | 6.1M | |
Other Liab | 83.3M | 59.9M | 92.4M | 84.5M | 76.1M | 67.7M | |
Net Tangible Assets | 63.1M | 57.1M | 153.7M | (102.2M) | (92.0M) | (87.4M) | |
Other Assets | 14.7M | 7.8M | 11.1M | 36K | 32.4K | 30.8K | |
Long Term Debt | 215.3M | 226.6M | 375.5M | 377.3M | 310.3M | 268.1M | |
Net Invested Capital | 426.6M | 528.7M | 418.4M | 578.1M | 438.1M | 507.4M | |
Non Current Liabilities Other | 88.2M | 20.4M | 73.6M | 8.5M | 6.8M | 6.5M | |
Net Working Capital | 317.7M | 458.7M | 344.3M | 438.9M | 216.0M | 376.8M | |
Property Plant Equipment | 2.9M | 35.1M | 11.1M | 9.0M | 10.4M | 11.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.